Eric Aguiar MD Overview
- Firm
- Aisling Capital
- Primary Position
-
Partner
- Primary Industry
-
Healthcare
- Active Board Seats
-
4
- Med. Deal Size
-
- Med. Valuation
-
Eric Aguiar MD General Information
Biography
Dr. Eric Aguiar serves as a Partner at Aisling Capital. He also serves as a Board Member at BridgeBio, Invitae, Biomea Fusion, Garuda Therapeutics, and Eidos Therapeutics. He serves as the Board Observer of PellePharm. Prior to Aisling, he was a partner at Thomas, McNerney, and Partners, a $600 million healthcare-focused venture capital and growth equity fund, from 2007 to 2015. He serves as Director at Eidos Therapeutics. He was a Managing Director of HealthCare Ventures, a healthcare venture capital fund, from 2001 to 2007. He was CEO of Genovo, Inc., a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also the executive director of TheraTech, Inc. He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997. His prior board service includes Amarin, CardioKine, Biohaven (acquired by Pfizer), Metaphore (merged with ActivBiotics), Oriel Therapeutics (acquired by Novartis), SkinMedica, Virdante Pharmaceuticals (acquired by Momenta) and 3-D Pharmaceuticals (acquired by Johnson & Johnson). He serves as Emeritus Advisor to Tufts University School of Medicine and is a member of the Council on Foreign Relations. He received his M.D. with honors from Harvard Medical School and his B.A. with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.
Contact Information
Address
- 489 Fifth Avenue
- Floor 10
- New York, NY 10017
- United States
Eric Aguiar MD Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Aisling Capital | Investor | Partner | New York, NY | Venture Capital |
Eric Aguiar MD Board Seats (4)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Biomea Fusion | Drug Discovery | Publicly Held | Formerly VC-backed | Redwood City, CA | |
BridgeBio Pharma | Biotechnology | Publicly Held | Formerly VC-backed | Palo Alto, CA | |
Garuda Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Cambridge, MA | |
PellePharm | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | San Francisco, CA |
Eric Aguiar MD Lead Partner on Deals (15)
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Garuda Therapeutics | 24-Jan-2023 | Early Stage VC (Series B) | Completed | Drug Discovery | Cambridge, MA | |
Garuda Therapeutics | 07-Sep-2021 | Completed | Drug Discovery | Cambridge, MA | ||
Biomea Fusion | 23-Dec-2020 | Completed | Drug Discovery | Redwood City, CA | ||
BridgeBio Pharma | 23-Jan-2019 | Completed | Biotechnology | Palo Alto, CA | ||
BridgeBio Pharma | 10-Apr-2018 | Completed | Biotechnology | Palo Alto, CA | ||
Eidos Therapeutics | 05-Apr-2018 | Completed | Drug Discovery | San Francisco, CA | ||
Biohaven | 16-Feb-2017 | Completed | Drug Discovery | Tortola, VI | ||
BridgeBio Pharma | 26-Mar-2016 | Completed | Biotechnology | Palo Alto, CA | ||
Invitae | 13-Oct-2014 | Later Stage VC (Series F) | Completed | Clinics/Outpatient Services | San Francisco, CA | |
Invitae | 10-Dec-2013 | Later Stage VC (Series E) | Completed | Clinics/Outpatient Services | San Francisco, CA |
Eric Aguiar MD Network (218)
Board Members (84)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Anders Hove MD | POGO Automatic | Venrock | Fremont, CA | |
John Childs | Biohaven | Self | Tortola, VI | |
PellePharm | BridgeBio Pharma | San Francisco, CA | ||
BridgeBio Pharma | BridgeBio Pharma | Palo Alto, CA | ||
Eidos Therapeutics | Self | San Francisco, CA |
Portfolio Executives (118)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
James Desiderio Ph.D | Garuda Therapeutics | Chief Regulatory Officer | 24-Jan-2023 | Cambridge, MA |
David DiGiusto Ph.D | Garuda Therapeutics | Chief Technology Officer | 24-Jan-2023 | Cambridge, MA |
Garuda Therapeutics | Chief Financial Officer | 24-Jan-2023 | Cambridge, MA | |
Garuda Therapeutics | Co-Founder | 24-Jan-2023 | Cambridge, MA | |
Garuda Therapeutics | Co-Founder | 24-Jan-2023 | Cambridge, MA |
Fund Team Members (16)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Alex Zisson | Thomas McNerney & Partners | Thomas McNerney & Partners Fund | Stamford, CT |
Alex Zisson | Thomas McNerney & Partners | Thomas McNerney & Partners II | Stamford, CT |
HealthCare Ventures | Cambridge, MA | ||
HealthCare Ventures | Cambridge, MA | ||
Aisling Capital | New York, NY |
Eric Aguiar MD Affiliated Funds (5)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Thomas McNerney & Partners Fund | Thomas McNerney & Partners | Venture - General | Liquidated | 2003 | ||||
HealthCare Ventures VIII | HealthCare Ventures | Venture - General | Closed | 2005 | ||||
Thomas McNerney & Partners II | Thomas McNerney & Partners | Venture - General | Liquidated | 2006 | ||||
Aisling Capital IV | Aisling Capital | Venture Capital - Later Stage | Fully Invested | 2016 | ||||
Aisling Capital V | Aisling Capital | Venture Capital - Later Stage | Closed | 2019 |
Eric Aguiar MD FAQs
-
Who is Eric Aguiar MD?
Dr. Eric Aguiar serves as a Partner at Aisling Capital.
-
How much does Eric Aguiar MD typically invest?
Eric Aguiar MD's median deal size is
. -
What is Eric Aguiar MD’s main position?
Eric Aguiar MD’s primary position is Partner.
-
What are the contact details for Eric Aguiar MD?
Eric Aguiar MD’s email address is ea
and his phone number is +1 (212) . -
How many active board seats does Eric Aguiar MD hold?
Eric Aguiar MD holds 4 board seats including Biomea Fusion, BridgeBio Pharma, Garuda Therapeutics, and PellePharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »